drugset
drugset / Trial / NCT06633783

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

NCT06633783 ↗

Phase 3 Not yet recruiting 370 enrolled Hangzhou Jiuyuan Gene Engineering Co. Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.

Timeline

Start
2024-10-30
Primary completion
2026-05-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 2.4 mg Subcutaneous

Indications

obesity disorder